Novo Nordisk's Subcutaneous Semaglutide Shows Positive Action In Type 2 Diabetes

Novo Nordisk A/S NVO has announced headline results from a Phase 2 trial of CagriSema, a once-weekly subcutaneous combination of semaglutide and amylin analog cagrilintide.
In the trial, the mean baseline HbA1c was 8.4%, and the mean baseline body weight was 106 kg.
After 32 weeks, people treated with CagriSema achieved an HbA1c reduction of 2.18%-points compared to a reduction of 1.79%-points for people treated with semaglutide and 0.93%-points with cagrilintide alone.
Related: Novo Nordisk Shares Fall After Q2 Earnings Despite Raised Annual Outlook.
CagriSema achieved a higher body weight reduction of 15.6% compared to a reduction of 5.1% for people treated with semaglutide and 8.1% with cagrilintide alone.
In the trial, CagriSema appeared to have a safe and well-tolerated profile.
Novo Nordisk plans to initiate a phase 3 development program for CagriSema for type 2 diabetes in 2023.
The CagriSema (2.4 mg semaglutide and 2.4 mg cagrilintide) phase 3 program for overweight and obesity, REDEFINE, is expected to begin in Q4 of 2022.
Price Action: NVO shares are up 3.54% at $108.25 on the last check Monday.